Abstracts tagged "safety and sarcoidosis"

Abstract Number: 2904 • 2017 ACR/ARHP Annual Meeting
Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)
Deborah Puyraimond-Zemmour¹, Catherine Chapelon-Abric², David Saadoun³, Diane Bouvry⁴, Marc Ruivard⁵, Marc Andre⁶, Laurent Perard⁷, Pascal Sève⁸ and Patrice Cacoub⁹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France, Paris, France, ²AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ⁴Hopital Avicenne, Department of Pneumology, Bobigny, France, Bobigny, France, ⁵CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁶CHU Montpied, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁷Department of Internal Medicine, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France, ⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Background/Purpose: CS is a life-threatening condition that accounts for 85% of sarcoidosis-related deaths in Japan and 13-25% in America. The objective is to evaluate the…